Literature DB >> 3012007

Hyperdiploidy and chromosomal rearrangements define the anaplastic variant of Wilms' tumor.

E C Douglass, A T Look, B Webber, D Parham, J A Wilimas, A A Green, P K Roberson.   

Abstract

Flow cytometric measurement of the DNA content of Wilms' tumor cells revealed a striking correspondence with the histologic subtype and treatment outcome. In the 48 cases studied, a hyperdiploid DNA content ranging from 1.7 to 3.2 times the result for normal diploid cells distinguished all but one of the ten anaplastic tumors. Lower values, from 1.0 to 1.4 times the diploid DNA content, characterized the nonanaplastic specimens. By Kaplan-Meier analysis, the probability of achieving 3 years of relapse-free survival was significantly lower in the group with higher DNA content (0.42 v 0.87, P less than .01). Analysis of banded chromosomes for a subset of 22 patients contributed important information beyond the flow cytometric study. Cases of anaplasia associated with poorer responses to therapy showed numerous complex translocations, whereas all others lacked such changes. By combining flow cytometric techniques and conventional methods of chromosome analysis, it should be possible to identify those patients with Wilms' tumor who are most likely to fail therapy. The biologic implication of these findings is that the development of clinical drug resistance in Wilms' tumor is a result of the genetic instability of the malignant clone.

Entities:  

Mesh:

Year:  1986        PMID: 3012007     DOI: 10.1200/JCO.1986.4.6.975

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  DNA quantitation of Wilms' tumour (nephroblastoma) using flow cytometry and image analysis.

Authors:  S Gururangan; A Dorman; R Ball; B Curran; M Leader; F Breatnach; A O'Meara
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

2.  Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma.

Authors:  S L Cohn; A W Rademaker; H R Salwen; W A Franklin; F Gonzales-Crussi; S T Rosen; K D Bauer
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

3.  Heterogeneity of Wilms' tumour blastema. An immunohistological study.

Authors:  F W Albeda; W M Molenaar; L de Leij; A H Thijs-Ipema
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Ploidy changes between diagnosis and relapse in childhood renal tumours.

Authors:  A O'Meara; S Gururangan; R Ball; E Kay; A Kelsey
Journal:  Urol Res       Date:  1993

5.  Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.

Authors:  D J Hazen-Martin; G G Re; A J Garvin; D A Sens
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

6.  Cytogenetic investigations of solid tumours of children.

Authors:  A D Pearson; M M Reid; E V Davison; N Bown; A J Malcolm; A W Craft
Journal:  Arch Dis Child       Date:  1988-09       Impact factor: 3.791

7.  Congenital mesoblastic nephroma: possible prognostic and management value of assessing DNA content.

Authors:  J C Barrantes; C Toyn; K R Muir; S E Parkes; F Raafat; A H Cameron; H B Marsden; J R Mann
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

8.  Prognostic relevance of DNA content in childhood renal tumours.

Authors:  S Kumar; H B Marsden; R A Cowan; J M Barnes
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

9.  A non-diploid DNA status is linked to poor prognosis in renal cell cancer.

Authors:  Franziska Büscheck; Christoph Fraune; Martina Kluth; Maximilian Lennartz; Ronald Simon; Claudia Hube-Magg; Christian Morlock; Silvano Barbieri; Carolin Wahl; Christian Eichelberg; Christina Möller-Koop; Doris Höflmayer; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink
Journal:  World J Urol       Date:  2020-05-02       Impact factor: 4.226

10.  DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators.

Authors:  F K Niggli; J E Powell; S E Parkes; K Ward; F Raafat; J R Mann; M C Stevens
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.